araag2/HINT huggingface dataset:
Clinical trial NCT00683878 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, dapagliflozin, placebo matching dapagliflozin, thiazolidinedione (pioglitazone)
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, ≥ 18 years old, with type 2 diabetes and with inadequate glycemic
             control

          -  All subjects must have central laboratory pre-randomization A1C ≥ 7.0 and ≤ 10.5%

          -  C-peptide ≥ 1.0 ng/mL (0.34 nmol/L)

          -  Body Mass Index ≤ 45.0 kg/m²

        Exclusion Criteria:

          -  AST and /or ALT > 2.5 times the upper limit of normal

          -  Serum total bilirubin > 2 mg/dL (34.2 µmol/L)

          -  Creatinine kinase > 3.0 times the upper limit of normal

          -  Symptoms of severely uncontrolled diabetes

          -  Serum creatinine ≥ 2.0 mg/dL

          -  Calculated Cr-Clearance < 50 ml/min (calculated by Cockroft-Gault formula)

          -  Currently unstable or serious cardiovascular, renal, hepatic, hematological,
             oncological, endocrine, psychiatric, or rheumatic diseases
Clinical trial NCT01292460 (phase 3, status: completed)
Conditions: ocular hypertension, open-angle glaucoma
ICD codes: H40.053, H40.051, H40.052, H40.059, H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131
Drugs: timolol/ fdc/ placebo/ tafluprost
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 18 years or more

          -  A diagnosis of ocular hypertension or open-angle glaucoma and prior use of timolol or
             prostaglandin.

          -  Meet specific IOP level at visit 1 (screening), visit 2 (run-in) and visit 3
             (baseline).

          -  Meet specific visual acuity score

          -  Are willing to follow instructions

          -  Have provided a written informed consent

        Exclusion Criteria:

          -  Females who are pregnant, nursing or planning pregnancy

          -  IOP of 35 mmHg or greater

          -  Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular or
             pigmentary glaucoma in either eye

          -  Suspected contraindication or hypersensitivity to study medications tafluprost or
             timolol (e.g. asthma, low pulse)or to wash-out medication brinzolamide

          -  Glaucoma filtration surgery or any other ocular surgery (including ocular laser
             procedures) within 6 months prior to Screening

          -  Use of contact lenses at Screening or during the study

          -  Presence of any abnormality or significant illness that could be expected to interfere
             with the patient safety or study parameters

          -  Current participation in another clinical trial within the last 30 days
Clinical trial NCT01571362 (phase 3, status: completed)
Conditions: chronic pain, low back pain, analgesia
ICD codes: G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3, M54.50, M54.51, M54.59, P04.0
Drugs: alo-02, placebo
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Moderate-to-severe chronic low back pain present for at least 3 months.

          -  Require a continuous around-the-clock opioid analgesic for an extended period of time.

          -  Refrain from taking other opioid and non-opioid medications during the study.

        Exclusion Criteria:

          -  Active or within a past 2 years a history of lumbosacral radiculopathy or chronic low
             back pain due to other underlying disorders such as spinal stenosis with neurologic
             impairment, cancer, infection, or post-surgical intervention.

          -  Documented diagnosis of ongoing pain due to other chronic pain conditions which may
             interfere with assessment of chronic low back pain.

          -  Active or ongoing or history of alcohol or drug abuse.
Clinical trial NCT00262522 (phase 3, status: completed)
Conditions: human immunodeficiency virus infections
ICD codes: Z21
Drugs: lopinavir/ritonavir (lpv/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (nrtis), lopinavir/ritonavir (lpv/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (nrtis), lopinavir/ritonavir (lpv/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (nrtis), lopinavir/ritonavir (lpv/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (nrtis)
SMILES: OC(=O)[C@@H]1CCCN1, OC(=O)[C@@H]1CCCN1, OC(=O)[C@@H]1CCCN1, OC(=O)[C@@H]1CCCN1
Eligibility criteria:

        Inclusion Criteria

          -  Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral
             naïve adults at least 18 years of age with < 7 days of prior antiretroviral therapy.

          -  Subjects had plasma HIV-1 ribonucleic acid (RNA) levels >= 1,000 copies/mL at
             screening and were not acutely ill.

          -  Female subjects were nonpregnant and nonlactating.

        Exclusion Criteria

          -  Subjects were excluded if screening laboratory analyses showed any of the following
             abnormal laboratory results:

               -  Presence of hepatitis B surface antigen (HBsAg)

               -  Hemoglobin <= 8.0 g/dL

               -  Absolute neutrophil count <= 750 cells/microliter

               -  Platelet count <= 50,000 per mL

               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= 3.0 x Upper
                  Limit of Normal (ULN)

               -  Calculated creatinine clearance < 50 mL/min
Clinical trial NCT00288379 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: formoterol, budesonide/formoterol
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosed history of asthma for at least 6 months

          -  Mild and stable asthma, only using β2-agonists as needed for the last 4 weeks.

          -  FEV1 >70% of predicted normal value (post-bronchodilator value).

          -  Skin prick test positive to pollen, animal dander or house dust mite.

        Exclusion Criteria:

          -  Any significant respiratory disease, other than asthma.

          -  Upper or lower respiratory tract infection within 4 weeks before inclusion.

          -  Use of:

               1. inhaled glucocorticosteroid treatment for the last 8 weeks prior to inclusion or
                  ever used oral glucocorticoid treatment for asthma.

               2. inhaled long-acting or oral b2-agonists, anticholinergic bronchodilators,
                  cromones, antihistamines, theophyllines and anti-leukotrienes within 2 weeks of
                  screening.

               3. regular NSAIDs
Clinical trial NCT00210990 (phase 3, status: completed)
Conditions: urinary tract infections, pyelonephritis
ICD codes: P39.3, N39.0, O86.20, O86.29, N99.531, O03.38, N99.521, A02.25, D86.84, N10, N11.1, N11.0
Drugs: doripenem
SMILES: [H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of complicated lower urinary tract infection or pyelonephritis

        Exclusion Criteria:

          -  Women who are pregnant, nursing or of child-bearing potential and not using a
             medically accepted, effective method of birth control

          -  History of moderate or severe hypersensitivity reactions to antibiotic medications
Clinical trial NCT01315678 (phase 3, status: completed)
Conditions: pseudomonas aeruginosa infection
ICD codes: A41.52, J15.1, P23.5, B96.5
Drugs: liposomal amikacin for inhalation (arikayce™) using the pari investigational eflow® nebulizer., tobramycin inhalation solution using a pari lc® plus nebulizer.
SMILES: NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Written informed consent or assent

          -  Confirmed diagnosis of CF

          -  History of chronic infection with Pseudomonas aeruginosa

          -  Sputum culture positive for Pseudomonas aeruginosa at Screening

          -  FEV1 ≥ 25% of predicted value at Screening

        Key Exclusion Criteria:

          -  FEV1 <25% of predicted at Screening

          -  History of major complications of lung disease within 8 weeks prior to Screening

          -  Hemoptysis of ≥60 mL in a 24-hour period within 4 weeks prior to Screening

          -  History of positive culture for Burkholderia cepacia within 2 years prior to Screening

          -  History of pulmonary tuberculosis or non-tuberculous mycobacterial lung disease
             treated within 2 years prior to Screening or requiring treatment at the time of
             screening

          -  History of Allergic Broncho-Pulmonary Aspergillosis or any other condition requiring
             systemic steroids at a dose ≥ equivalent of 10 mg/day of prednisone within 3 months
             prior to Screening

          -  Presence of any clinically significant cardiac disease

          -  History of lung transplantation

          -  Daily, continuous oxygen supplementation or nighttime supplemental oxygen requirement
             of greater than 2 L/min

          -  Administration of any investigational products within 8 weeks prior to study Day 1

          -  Smoking tobacco or any substance within 6 months prior to screening or anticipated
             inability to refrain from smoking throughout the study
Clinical trial NCT01296412 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin, liraglutide, glimepiride, metformin
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN(C)C(=N)NC(N)=N, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion criteria

          -  Type 2 diabetes mellitus.

          -  On stable dose of metformin monotherapy at a dose of at least 1500 mg per day for at
             least 12 weeks and a hemoglobin A1C ≥7.0% and ≤11.0%.

          -  Capable of using a liraglutide pen device.

        Exclusion criteria

          -  History of Type 1 Diabetes mellitus.

          -  Use of any oral antihyperglycemic agent (AHA) besides metformin, within the prior 12
             weeks of screening.

          -  Cardiovascular disorders within the past 3 months including acute coronary syndrome or
             new or worsening symptoms of coronary heart disease, coronary artery intervention,
             stroke, or transient ischemic neurological disorder.

          -  Impaired liver function.

          -  Impaired kidney function.

          -  History of malignancy or clinically important hematological disorder that requires
             disease-specific treatment (chemotherapy, radiation therapy, surgery) or, in the
             opinion of the investigator, is likely to recur during the duration of the study.

          -  History of leukemia, lymphoma, aplastic anemia, myeloproliferative or myelodysplastic
             diseases, thrombocytopenia, or malignant melanoma, regardless of the time since
             treatment.

          -  Pregnancy or breastfeeding, or intention to become pregnant or donate eggs within the
             projected duration of the study.

          -  Participation in another study with an investigational drug or device within 12 weeks
             prior to screening.

          -  History of hypersensitivity or any contraindication to sitagliptin, liraglutide,
             glimepiride, or metformin based upon the labels of the country of the investigational
             site.

          -  Participation in a weight loss program and not yet in maintenance phase, or starting
             of a weight loss medication (such as orlistat or phentermine) within the prior 8
             weeks.

          -  Surgery within the prior 4 weeks or major surgery planned during the study.

          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine
             neoplasia syndrome type 2 (MEN 2).

          -  User of recreational or illicit drugs or recent history (within the last year) of drug
             abuse or increased alcohol consumption.
Clinical trial NCT00199927 (phase 3, status: completed)
Conditions: chronic nephropathy, proteinuria, hypertension
ICD codes: R80.0, R80.8, R80.9, R80.1, R80.2, R80.3, O12.10, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: fluvastatin, standard therapy
SMILES: CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  age >16 years

          -  hypertension, defined as a systolic or diastolic blood pressure > 140 or 90 mmHg
             respectively (or less in patients with concomitant antihypertensive therapy)

          -  creatinine clearance >20 ml/min/1.73m2 (with variation of less than 30% in the 3
             months prior to study entry)

          -  urinary protein excretion rate persistently > 1 g/24 hours (average of at least two
             measurements in two urine collections two weeks apart) without evidence of urinary
             tract infection or overt heart failure (New York Heart Association class III or more)

          -  written informed consent

        Exclusion criteria:

          -  specific contraindication to statin therapy because of a previous coronary event or
             serum LDL-cholesterol levels > 190 mg/dL despite a low cholesterol (<200 mg/day) diet
             and a saturated fatty acid in take less than 7% of total calories will not be included

          -  chronic treatment with corticosteroids, nonsteroidal anti-inflammatory drugs, or
             immunosuppressive drugs

          -  acute myocardial infarction or cerebrovascular accident in the six months preceding
             the study - severe uncontrolled hypertension (diastolic blood pressure >115 and/or
             systolic blood pressure >220 mmHg)

          -  evidence or suspicion of renovascular disease, obstructive uropathy, type 1 diabetes
             mellitus, vasculitides, cancer

          -  elevated serum aminotransferase concentrations - chronic cough

          -  history of poor tolerance or allergy to ACEi, ATA or statins

          -  drug or alcohol abuse

          -  pregnancy, breast feeding and ineffective contraception

          -  legal incapacity and/or other circumstances rendering the patient unable to understand
             the nature, scope and possible consequences of the trial.
Clinical trial NCT00404924 (phase 3, status: completed)
Conditions: non-small-cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: zd6474 (vandetanib)
SMILES: COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with Non-small cell lung cancer for which the standard cancer treatments of
             surgery, chemotherapy, radiation or other anticancer drugs are no longer appropriate
             treatments for you.

        Exclusion Criteria:

          -  Patients who have had standard cancer treatments of surgery, chemotherapy or other
             systemic anti-cancer therapy within 4 weeks before start of study therapy.

          -  Three or more prior chemotherapy regimens.

          -  Significant cardiovascular events.
Clinical trial NCT01130493 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: ipx066, cle
SMILES: C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosed with idiopathic Parkinson's Disease (PD).

          2. At least 30 years old at the time of PD diagnosis.

          3. Currently being treated with carbidopa/levodopa/entacapone (CLE) and on a stable
             regimen of conventional LD for at least 4 weeks and:

               -  Requiring a total daily levodopa (LD) dose of at least 400 mg

               -  Having a minimum dosing frequency of four times per day.

               -  Individual CD-LD or CLE doses that contain an LD dose which is a multiple of 50
                  mg.

          4. Able to differentiate "on" state from "off" state.

          5. Have predictable "off" periods.

          6. Amantadine, anticholinergics, selective monoamine oxidase (MAO) type B inhibitors
             (e.g., selegiline, rasagiline) or dopamine agonists are allowed as long as the doses
             and regimens have been stable for at least 4 weeks prior to Screening and the therapy
             is intended to be constant throughout the course of the study.

          7. Agrees to use a medically acceptable method of contraception throughout the study and
             for 1 month afterward.

        Exclusion Criteria:

          1. Diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome.

          2. Nonresponsive to LD therapy.

          3. Prior functional neurosurgical treatment for PD (e.g., ablation or deep brain
             stimulation) or if such procedures are anticipated during study participation.

          4. Received within 4 weeks of Screening or planning to take during participation in the
             clinical study: any controlled-release LD product, tolcapone, apomorphine,
             nonselective MAO inhibitors, or antipsychotics including neuroleptic agents for the
             purpose of treating psychosis or bipolar disorder.

          5. Allergy or hypersensitivity to CD, LD, entacapone, riboflavin, Yellow Dye #5
             (tartrazine), citrus fruit or grape juice.

          6. History of or currently active psychosis.

          7. Active or prior medical conditions such as peptic ulcers or prior surgical (e.g.,
             bowel) procedures that would interfere with LD absorption.

          8. Active or history of narrow-angle glaucoma.

          9. History of malignant melanoma or a suspicious undiagnosed skin lesion.

         10. History of myocardial infarction with residual atrial, nodal, or ventricular
             arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome or
             nontraumatic rhabdomyolysis.

         11. Received any investigational medications during the 4 weeks prior to Screening.

         12. Unable to swallow large pills (e.g., large vitamin pills).

         13. Pregnant or breastfeeding.

         14. Subjects who are unable to complete a symptom diary.
Clinical trial NCT00268177 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: salmeterol/fluticasone propionate 50/500mcg diskus
SMILES: OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Established clinical history of chronic obstructive airways disease.

          -  Must be current or ex-smokers with a smoking history of at least 10 pack-years (e.g.
             20 cigarettes/day for 10 years or 10 cigarettes/day for 20 years).

          -  Must have reduced lung function, defined as a Forced Expiratory Volume in 1 second
             (FEV1) of between 40-80% of predicted normal values.

        Exclusion Criteria:

          -  Diagnosis of any other serious disease and must have a chest X-ray to eliminate a
             diagnosis other than COPD.
Clinical trial NCT00424476 (phase 3, status: completed)
Conditions: systemic lupus erythematosus
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: placebo, belimumab 1 mg/kg, belimumab 10 mg/kg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Clinical diagnosis of SLE by ACR criteria.

          -  Active SLE disease.

          -  Autoantibody-positive.

          -  On stable SLE treatment regimen.

        Key Exclusion Criteria:

          -  Pregnant or nursing

          -  Have received treatment with any B cell targeted therapy.

          -  Have received treatment with a biological investigational agent in the past year.

          -  Have received IV cyclophosphamide within 180 days of Day 0.

          -  Have severe lupus kidney disease.

          -  Have active central nervous system (CNS) lupus.

          -  Have required management of acute or chronic infections within the past 60 days.

          -  Have current drug or alcohol abuse or dependence.

          -  Have a historically positive test or test positive at screening for HIV, hepatitis B,
             or hepatitis C.
Clinical trial NCT00352183 (phase 3, status: completed)
Conditions: cardiovascular diseases
ICD codes: A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30
Drugs: fenofibrate/simvastatin, simvastatin
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Mixed dyslipidemia

        Exclusion Criteria:

          -  Diabetes,

          -  Known hypersensitivity to fenofibrate or simvastatin,

          -  Pregnant or lactating women,

          -  Contra-indication to fenofibrate or simvastatin,

          -  Unstable or severe cardiac disease.